Puhe BioPharma's WRN inhibitor PH027-1 has been approved for IND Puhe BioPharma settles in Bayer Co. Lab as one of the first batch of companies Puhe BioPharma and Bayer Enter into Global License Agreement for Clinical Phase I PRMT5 Inhibitor PH001 Clinical Phase III National Investigator Conference Phase III Clinical Study of Class 1 new drug YK-029A Tablet developed by Suzhou Puhe Biopharma independently completed the First Patient Enrollment Breaking through the Difficult Target of Lung Cancer Treatment - Suzhou Puhe Biopharma PH001 (YK-029A) was approved by the National Medical Products Administration to carry out Phase III Clinical Trial